|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
February 2007FeaturesCover Story Cancer Carve-outs: Is It Time?It’s not a new idea; carving out cancer was once regarded as a practical step – until the managed care backlash hit. As the oncology landscape changes, though, there is renewed interest. Do cancer carve-outs deserve a second look? Diagnostics Cancer Biomarkers: Where Medicine, Business, and Public Policy IntersectHow the molecular revolution would change cancer care. Policy Generic Biopharmaceutical Drugs: An Economic and Policy AnalysisFostering an environment that allows biologic follow-ons and encourages new therapies is tricky. Can all the parties’ economic issues be resolved? Leading Edge Gene Therapy: Science in Slow MotionCautiously optimistic, gene therapy researchers are targeting devastating diseases. Big pharma’s money is needed to increase the momentum. Clinical Are We There Yet? Seeking the Value of Pharmacogenetics in Cardiovascular CarePresentations at the 2006 Scientific Sessions of the American Heart Association addressed how best to harness the potential of this science. DepartmentsOpeners Everything Old Is New AgainPeter Allen and Carole Bayer Sager were right about everything old. Editorial Say What?David B. Nash, MD, MBA, looks at Medicare coverage policies. Washington Watch FDA Proposes Guidelines for Access to Experimental TherapiesAccess to experimental therapies. Diagnostics and Devices Molecular Imaging Modernizes MedicineThe promise of molecular imaging. DrugTrack Approvals, FDA Actions, Clinical Trials
Bob Carlson, MHA Biotech Business New England Health Plan Relaxes Access to OmalizumabMajor Northeast health plan removes prior authorization for one biologic. Trends Biotech Proving a Formidable Provider to Pharma InnovationJoint ventures benefit innovation. |
|||||